Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. - Wikidata - awgldk - TriplyDB

Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.

Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.

http://www.wikidata.org/entity/Q34995048

about

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources.A review of capecitabine-based adjuvant therapy for gastric cancer in the Chinese population.Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer.Estimation of population-based utility weights for gastric cancer-related health states.Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.

P2860

Q37706099-6852AD36-805F-40EF-A59A-B26C88956B37 Q39015252-9F1F8A22-B27B-4B92-B907-05F7B2256546 Q42378517-5A049434-67D9-4F48-B240-35B482301A54 Q47291560-6105CF4B-0C43-4721-A336-7D251126693F Q50632474-CD5FE452-B92E-41E5-BF8D-B56FC5B44316 Q55214722-F8C0C0C9-6FEE-45DE-9D00-06FBBEB31A55 Q55514438-919C13BB-78EA-45F6-81D4-E1912DEC41D6

P2860

Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.

http://www.wikidata.org/entity/Q34995048

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Cost-effectiveness analysis of ...... c cancer after D2 gastrectomy.

@ast

Cost-effectiveness analysis of ...... c cancer after D2 gastrectomy.

@en

Cost-effectiveness analysis of ...... c cancer after D2 gastrectomy.

@nl

type

label

Cost-effectiveness analysis of ...... c cancer after D2 gastrectomy.

@ast

Cost-effectiveness analysis of ...... c cancer after D2 gastrectomy.

@en

Cost-effectiveness analysis of ...... c cancer after D2 gastrectomy.

@nl

prefLabel

Cost-effectiveness analysis of ...... c cancer after D2 gastrectomy.

@ast

Cost-effectiveness analysis of ...... c cancer after D2 gastrectomy.

@en

Cost-effectiveness analysis of ...... c cancer after D2 gastrectomy.

@nl

P1433

Q34995048-EF70CECA-7BAE-449D-BB4C-C3BE1FA68327

P1476

Q34995048-82B39F3B-8995-4260-ACCD-8390DDBC6446

P2093

Q34995048-0A4D04E2-A845-4EF6-BA2C-03DB1C5D4741

Q34995048-34F0EED4-AEDA-4A7D-B222-4A7419B31422

Q34995048-42C9CCC4-7880-4609-A68F-7F7547C30A42

Q34995048-52362569-C80B-4244-8B92-03336DA7053A

Q34995048-5E6B09CD-F020-4977-9356-15C04DCEF45A

P2860

Q34995048-038EAE11-4B78-43A1-86D6-6CB1CF34BE2B

Q34995048-0A987D93-EF4F-462B-8828-4A0E08DBA35C

Q34995048-0D04DDCF-770B-42FA-8DEB-A056BFDE47EF

Q34995048-21BD27DB-2933-4D07-85C2-0D81F4D260E4

Q34995048-2833F68E-8B50-4B1D-A21B-ADC8CBC96713

Q34995048-2B584C63-1065-4188-8143-14F2B29B0055

Q34995048-334E3A76-9713-45E4-A5F1-4058C7736656

Q34995048-374811D3-5826-4FEA-9F96-41EA42E8011B

Q34995048-3AA3657D-E810-4464-8926-EA698C7C2AEE

Q34995048-3C74CA3E-A3FE-4641-BE7A-E8B3077C8F69

P2888

Q34995048-F9BBE690-ADF9-44B5-AACF-781ED670B1C7

P304

Q34995048-618F9C41-EEE4-4242-B87F-665516E9F412

P31

Q34995048-C532B97D-AA22-4E96-973B-77CA1E89F632

P356

Q34995048-3842F8C3-DF84-421B-9AF4-7B0B21AFD089

P407

Q34995048-490B6BDB-B50E-48FA-875A-C21CC098691D

P478

Q34995048-5F7D892C-9841-4264-9ECC-3F336CCF9DBD

P577

Q34995048-1674ABA7-7B1D-42D6-A431-355482252BA8

P5875

Q34995048-747BCBF4-6B69-41AD-9FE6-200651077400

P6179

Q34995048-7BC024DE-98B6-4C21-89EF-AE650543F068

P698

Q34995048-29AF8593-0B3E-44E8-81A1-91B10D40A7BA

P921

Q34995048-36FF18C1-4707-4FD1-ABA4-A6CD789D0006

P932

Q34995048-04EE86B5-44C0-4CD8-89B6-69396B11CD17

P356

1471-2407-14-984

P1433

P1476

Cost-effectiveness analysis of ...... c cancer after D2 gastrectomy.

@en

P2093

Bin Wu

http://www.w3.org/2001/XMLSchema#string

Gang Zhao

http://www.w3.org/2001/XMLSchema#string

Jian Cai

http://www.w3.org/2001/XMLSchema#string

Te Li

http://www.w3.org/2001/XMLSchema#string

Yuejuan Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

Challenges in developing evidence-based recommendations using the GRADE approach: the case of mental, neurological, and substance use disorders.

Clinical implications of dihydropyrimidine dehydrogenase inhibition.

Development of WHO guidelines on generalized cost-effectiveness analysis.

Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival

Treatment strategies in gastric cancer.

P2888

1471-2407-14-984

P304

984

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-14-984

http://www.w3.org/2001/XMLSchema#string

P407

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269820414

http://www.w3.org/2001/XMLSchema#string

P6179

1029642331

http://www.w3.org/2001/XMLSchema#string

P698

25526802

http://www.w3.org/2001/XMLSchema#string

P921

P932

4301844

http://www.w3.org/2001/XMLSchema#string